El interés en corto de Perspective Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Perspective Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Perspective Therapeutics (AMEX:CATX) Bolsa, Informe de interés en corto

Perspective Therapeutics

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics Inc

Macro Economic Events

WIIM

Economics

Gold is trading higher following November PCE data.

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher following November PCE data.

GSAT

Globalstar shares are trading higher following stock  purchases by a company director.

Benzinga readers pick which Magnificent 7 stock could have the best performance if there is a<a href="https://www.benzinga.com/topic/santa-claus-rally"> Santa Claus rally</a> to close 2024 and kickstart 2025.
What Happened: The majority of the <a href="https://www.benzinga.com/topic/magnificent-seven">Magnificent 7 stocks </a>have outperformed the S&amp;P 500 year-to-date in 2024. With a limited number of trading days left to close out the year, one last question on the mind of investors is whether there will be a Santa Claus rally.
The term &#8220;Santa Claus rally&#8221; was first used by Yale Hirsch in 1972 in the Stock Trader's Almanac. The term is associated with the last five trading days of a year and the first two days of the following year.
Check This Out: <a href="https://www.benzinga.com/general/education/24/12/42625025/santa-claus-rally-in-2024-poll-shows-investors-split-on-end-of-year-returns-57-say-this">Santa Claus Rally In 2024? Poll Shows Investors Split On End Of Year Returns, 57% Say This…</a>
Combine the Santa Claus rally potential and the Magnificent 7 outperformance in 2024, and you have the latest Benzinga poll.
"Which Magnificent 7 stock will do the best if there's a Santa Rally?" Benzinga asked.
The results were:
<ul>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): 28%</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 25%</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): 17%</li>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): 9%</li>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>): 9%</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): 7%</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): 5%</li>
</ul>
Nvidia was the winner of the poll with more than one-fourth of the vote, which comes as the stock is the top performer among the Mag 7 stocks for year-to-date and five-year gains. Trailing Nvidia was Tesla, with exactly one-fourth of the vote.
Amazon also received a double-digit percentage ranking third at 17%. The other Mag 7 stocks had much smaller percentages in the poll.
Read Also: <a href="https://www.benzinga.com/tech/24/11/42143676/which-magnificent-7-stock-should-doj-target-next-benzinga-poll-finds-over-50-say">Which Magnificent 7 Stock Should DOJ Target Next? Benzinga Poll Finds Over 50% Say&#8230;</a>
Why It's Important: The expectation for a Santa Claus Rally comes with major stock market indexes enjoying a strong 2024 and could add to their year-to-date gains.
Here are the current year-to-date returns of three of the largest market index ETFs.
<ul>
<li>SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>): +23.8%</li>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>): +28.1%</li>
<li>SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>): +12.7%</li>
</ul>
For comparison, here are the year-to-date returns of the Magnificent 7 stocks:
<ul>
<li>Nvidia: +177.8%</li>
<li>Tesla: +77.4%</li>
<li>Meta Platforms: +72.9%</li>
<li>Amazon: +49.8%</li>
<li>Alphabet: +38.3%</li>
<li>Apple: +35.8%</li>
<li>Microsoft: +18.7%</li>
</ul>
Nvidia has significantly outperformed the S&amp;P 500 and other major indexes and also the other Magnificent 7 stocks. The Benzinga poll shows that readers think Nvidia could go out on a high note in 2024 and kick 2025 off with a bang if there is a Santa Claus rally.
Only Microsoft trails the S&amp;P 500 and Invesco QQQ Trust year-to-date returns in 2024, showing the strength of the Magnificent 7 stocks this year. 
<a href="https://www.benzinga.com/tech/24/11/42121665/could-another-magnificent-7-stock-beat-nvidia-in-2025-poll-says-not-likely-27-pick-this-potential-winner">A recent Benzinga poll</a> asked if any Magnificent 7 stocks could beat Nvidia for stock returns in 2025. The results were:
<ul>
<li>None – Nvidia will dominate: 48%</li>
<li>Tesla: 27%</li>
<li>Amazon: 8%</li>
<li>Meta: 7%</li>
<li>Alphabet: 6%</li>
<li>Microsoft: 3%</li>
<li>Apple: 2%</li>
</ul>
The poll found the near-majority predicting Nvidia will have the strongest growth in 2025 and dominate the Magnificent 7 stocks once again.
Based on the recent polls, Benzinga readers don't expect the gains for Nvidia to stop anytime soon and a Santa Claus rally could accelerate the company's potential 2025 gains.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42352997/santa-rally-here-are-10-sp-500-stocks-that-historically-outperformed-in-decembers-second-half">Santa Rally: 10 S&amp;P 500 Stocks That Outperform In December&#8217;s Second Half</a></li>
</ul>
The study was conducted by Benzinga from Dec. 18 through Dec. 19, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 169 adults.
Image created using photos from Shutterstock.

Exclusives

Trading Ideas

AAPL

AMZN

GOOG

GOOGL

MSFT

NVDA

TSLA

Which Magnificent 7 Stock Will Do Best In Santa Claus Rally? Tesla Edged Out As 28% Select…

Deep-pocketed investors have adopted a bullish approach towards Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 59 extraordinary options activities for Carvana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 40% leaning bullish and 38% bearish. Among these notable options, 46 are puts, totaling $3,416,972, and 13 are calls, amounting to $1,001,995.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $300.0 for Carvana over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Carvana's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Carvana's whale activity within a strike price range from $60.0 to $300.0 in the last 30 days. 
<h3>Carvana Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734725418_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.2</td>
<td>$7.15</td>
<td>$8.0</td>
<td>$200.00</td>
<td>$800.0K</td>
<td>6.3K</td>
<td>1.6K</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$163.35</td>
<td>$161.2</td>
<td>$161.2</td>
<td>$60.00</td>
<td>$290.1K</td>
<td>2.2K</td>
<td>31</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$15.0</td>
<td>$13.5</td>
<td>$14.25</td>
<td>$220.00</td>
<td>$285.0K</td>
<td>3.6K</td>
<td>208</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.95</td>
<td>$7.1</td>
<td>$7.72</td>
<td>$200.00</td>
<td>$154.4K</td>
<td>6.3K</td>
<td>669</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$56.95</td>
<td>$56.5</td>
<td>$56.95</td>
<td>$250.00</td>
<td>$142.3K</td>
<td>45</td>
<td>101</td>
</tr>
</tbody>
</table>

<h3>About Carvana</h3>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
<h3>Carvana's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,238,104, with CVNA's price down by -0.48%, positioned at $221.91.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Carvana</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $298.3333333333333.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Carvana, which currently sits at a price target of $330. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Carvana, targeting a price of $245. 
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $320. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Carvana options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

CVNA

This Is What Whales Are Betting On Carvana

Whales with a lot of money to spend have taken a noticeably bullish stance on Zscaler.
Looking at options history for Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $550,210 and 6, calls, for a total amount of $567,390.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $200.0 for Zscaler during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Zscaler's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Zscaler's whale activity within a strike price range from $100.0 to $200.0 in the last 30 days. 
<h3>Zscaler Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734725413_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.9</td>
<td>$4.7</td>
<td>$4.95</td>
<td>$150.00</td>
<td>$420.7K</td>
<td>1.9K</td>
<td align="right">850</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$85.4</td>
<td>$84.05</td>
<td>$85.4</td>
<td>$100.00</td>
<td>$170.8K</td>
<td>20</td>
<td align="right">20</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.35</td>
<td>$8.95</td>
<td>$9.0</td>
<td>$185.00</td>
<td>$127.8K</td>
<td>691</td>
<td align="right">18</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$24.3</td>
<td>$23.85</td>
<td>$24.3</td>
<td>$200.00</td>
<td>$121.5K</td>
<td>33</td>
<td align="right">0</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$26.5</td>
<td>$25.95</td>
<td>$25.9</td>
<td>$200.00</td>
<td>$77.7K</td>
<td>60</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Zscaler</h3>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
<h3>Zscaler's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,339,536, the price of ZS is up by 2.4%, reaching $187.61.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 69 days from now.</li>
</ul>
<h3>Expert Opinions on Zscaler</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $224.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Zscaler, which currently sits at a price target of $190. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Zscaler, which currently sits at a price target of $222. 
&#x2A; An analyst from BTIG persists with their Buy rating on Zscaler, maintaining a target price of $238. 
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Positive rating on Zscaler with a target price of $225. 
&#x2A; An analyst from Keybanc persists with their Overweight rating on Zscaler, maintaining a target price of $245. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Zscaler, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Zscaler's Latest Options Trends

CoStar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) has outperformed the market over the past 10 years by 3.24% on an annualized basis producing an average annual return of 14.26%. Currently, CoStar Gr has a market capitalization of $29.29 billion. 
Buying $100 In CSGP: If an investor had bought $100 of CSGP stock 10 years ago, it would be worth $384.87 today based on a price of $71.44 for CSGP at the time of writing.
<h3>CoStar Gr's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734725410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

CSGP

Here's How Much $100 Invested In CoStar Gr 10 Years Ago Would Be Worth Today

Graco Inc. (NYSE:<a href="https://www.benzinga.com/stock/GGG#NYSE">GGG</a>), a leading manufacturer of fluid handling equipment, has made available on the "For Investors" page at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.graco.com&amp;esheet=54170101&amp;newsitemid=20241220353197&amp;lan=en-US&amp;anchor=www.graco.com&amp;index=1&amp;md5=2910d169943714442c70bb83738aeb2b">www.graco.com</a> unaudited supplemental financial information to recast the company's historic segment financial information on a basis that reflects its new organizational structure. As previously announced, effective January 1, 2025, the Company will classify its business into three reportable segments: Contractor, Industrial and Expansion Markets.
<ul>
<li>The Industrial segment, will consist of the newly formed Industrial Division and the Powder Division. The company's current Industrial and Lubrication Equipment Divisions, along with the Process Transfer Equipment business that is part of the company's existing Process Division, are being combined to form the new global Industrial Division. The Powder Division will remain unchanged.</li>
<li>The Expansion Markets segment will consist of the Expansion Markets Division and will focus on driving inorganic growth in new or adjacent markets. The company's existing environmental, semiconductor, high-pressure valves and electric motors businesses, together with select future ventures and acquisitions in new or adjacent markets, will reside within the Expansion Markets Division.
<ul>
<li>The Contractor segment, consisting of the Contractor Division, will remain unchanged as a reporting segment relative to prior periods.</li>
</ul>
</li>
</ul>

Graco Announces New Organizational Structure Effective January 1, 2025, Recasting Financial Information For 3 Segments: Contractor, Industrial, And Expansion Markets; Industrial to Include New Global Division; Powder Division Remains Unchanged; Expansion Focuses on Inorganic Growth; Contractor Segment Will Also Remain Unchanged

TNDM

Tandem Diabetes Care shares are trading higher amid strength in diabetes-related stocks following weight loss data from Novo Nordisk.

NBT Bancorp Inc. ("NBT") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTB#NASDAQ">NBTB</a>) announced that it has received regulatory approval to complete the proposed merger (the "Merger") of Evans Bancorp, Inc. ("Evans") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVBN#NYSE">EVBN</a>) with and into NBT and Evans Bank, N.A. ("Evans Bank") with and into NBT Bank, N.A. ("NBT Bank"). The Office of the Comptroller of the Currency approved the merger of Evans Bank with and into NBT Bank, and NBT received a waiver from the Federal Reserve Bank of New York for any application with respect to the merger of Evans with and into NBT.
On December 20, 2024, the shareholders of Evans voted to approve the Merger. Evans reported&nbsp;over 75% of the issued and outstanding shares of Evans were represented at a special shareholder meeting and over 96% of the votes cast were voted to approve the Merger.

EVBN

NBTB

NBT Bancorp Receives Regulatory Approval To Complete The Merger With Evans Bancorp, Shareholders Approve Merger

Elon Musk's role in the political dynamics of President-elect Donald Trump's team took center stage during this week's <a href="https://www.benzinga.com/24/12/42624528/government-shutdown-stocks-wobble-paychecks-delayed-holiday-travel-could-change-heres-what-you-need-to-know">government shutdown drama</a> as the billionaire's often scathing criticism of a bipartisan spending bill unleashed a wave of chaos on Capitol Hill.
Musk's social media posts, which by some accounts exceeded hundreds, depict his influence over GOP lawmakers and highlighted the outsized role he now plays and will likely continue to play in Trump's administration.
Republicans were not happy with the proposed version of the spending bill, though House Speaker Mike Johnson "believed that he could get enough Republicans to join most Democrats&#8221; to pass the bill and avert a shutdown, Russell Berman <a href="https://www.theatlantic.com/technology/archive/2024/12/elon-musk-x-congress-shutown/681120/">noted</a> in The Atlantic. It turns out, though, that the person he really needed to persuade was Musk.
<h2 class="wp-block-heading">Here's How It Rolled Out This Week</h2>
On Wednesday, Musk took to cyberspace lambasting the spending bill on X, calling it "criminal" and urging his 170 million followers to pressure Congress. His posts, which triggered strong reaction among House Republicans, were replete with threats. "Any member of the House or Senate who votes for this outrageous spending bill deserves to be voted out in two years!"
Johnson <a href="https://www.foxnews.com/video/6366181582112">told</a> Fox &amp; Friends Wednesday that he'd been in direct communication with Musk and entrepreneur Vivek Ramaswamy, attempting to explain the bill's nuances. Lobbying the two unelected billionaires, who are Trump &#8216;s picks to trim government waste, went on until the wee hours. Johnson admitted to Fox that he didn't get anywhere with the two.
Following Musk's tweets badgering House members, he also told his followers to call their representatives: "They are trying to get this passed today while no one is paying attention,&#8221; Musk warned.
<h2 class="wp-block-heading">Bernie Sanders Speaks Out: &#8216;President Elon Musk&#8217;</h2>
Sanders responded with a Wednesday tweet of his own, <a href="https://www.washingtonpost.com/politics/2024/12/19/co-president-elon-musk-trump-ally-tests-influence-spending-fight/">noted</a> the Washington Post. &#8220;Democrats and Republicans spent months negotiating a bipartisan agreement to fund our government. The richest man on Earth, President Elon Musk, doesn&#8217;t like it. Will Republicans kiss the ring? Billionaires must not be allowed to run our government.&#8221;
Axios' Mike Allen <a href="https://www.axios.com/2024/12/19/behind-the-curtain-musks-america">called</a> Musk "arguably the most powerful person in business, the most powerful man in media and, at least at this moment, the most powerful man in politics."
GOP lawmakers, already uneasy about the bill, folded under the pressure of Musk's threats, demonstrating what Allen referred to as the "new playbook" for conservative influence: direct, real-time social media lobbying.
"This much power, across this many pillars of society, is without precedent. Musk yesterday single-handedly, his voice amplified by his day-long bombardment of scores of tweets on his X platform, sank a 1,547-page, bipartisan House spending bill aimed at preventing a government shutdown on 12:01 AM Saturday," wrote Allen.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42624528/government-shutdown-threat-stocks-wobble-holiday-travel-and-paychecks-could-face-delays-what-you-need-to-know">Government Shutdown Threat: Holiday Travel, Paychecks Could Face Delays If No Deal Reached</a></li>
</ul>
Photo Frederic-Legrand Shutterstock.

Government

Politics

Bernie Sanders Blasts 'President Elon Musk': Others Join Chorus As Government Shutdown Looms

Analysts' ratings for Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) over the last quarter vary from bullish to bearish, as provided by 50 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">26</td>
<td align="right">23</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">17</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $244.48, a high estimate of $290.00, and a low estimate of $197.00. This upward trend is evident, with the current average reflecting a 6.12% increase from the previous average price target of $230.38.
<img src="https://www.benzinga.com/files/images/story/2024/1734724858_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Amazon.com. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Andrew Quail</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Michael Morton</td>
<td>MoffettNathanson</td>
<td>Raises</td>
<td>Buy</td>
<td>$248.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Alex Haissl</td>
<td>Redburn Atlantic</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$197.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Tom Forte</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Lee Horowitz</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$232.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$246.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$285.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$236.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$223.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$245.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Wlodarczak</td>
<td>Pivotal Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$260.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amazon.com. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amazon.com compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amazon.com's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AMZN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amazon.com analyst ratings.</a>
<h2>Unveiling the Story Behind Amazon.com</h2>
Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 75% of total, followed by Amazon Web Services' cloud computing, storage, database, and other offerings (15%), advertising services (5% to 10%), and other the remainder. International segments constitute 25% to 30% of Amazon's non-AWS sales, led by Germany, the United Kingdom, and Japan.
<h3>Unraveling the Financial Story of Amazon.com</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Amazon.com's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.04%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Amazon.com's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.65%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Amazon.com's ROE excels beyond industry benchmarks, reaching 6.19%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Amazon.com's ROA excels beyond industry benchmarks, reaching 2.69%. This signifies efficient management of assets and strong financial health.
Debt Management: Amazon.com's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

50 Analysts Assess Amazon.com: What You Need To Know

9 analysts have expressed a variety of opinions on Interactive Brokers Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $176.78, a high estimate of $214.00, and a low estimate of $163.00. Surpassing the previous average price target of $156.78, the current average has increased by 12.76%.
<img src="https://www.benzinga.com/files/images/story/2024/1734724850_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Interactive Brokers Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$190.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$214.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Daniel Fannon</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$152.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Interactive Brokers Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Interactive Brokers Gr compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Interactive Brokers Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Interactive Brokers Gr's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IBKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Interactive Brokers Gr analyst ratings.</a>
<h2>Unveiling the Story Behind Interactive Brokers Gr</h2>
Interactive Brokers is an online brokerage that generates trading commissions (around 31% of net revenue) from facilitating trading in a wide range of products, including equity, options, futures, foreign exchange, bonds, mutual funds, and exchange-traded funds. Interactive Brokers also generates net interest income (about 64% of net revenue) from idle client cash and earns fees (about 6% of net revenue) from ancillary services. Principal trading and other miscellaneous activities are small (about 5% of net revenue). The firm derives about 70% of its net revenue from the US and 30% from international markets.
<h3>Interactive Brokers Gr's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Interactive Brokers Gr showcased positive performance, achieving a revenue growth rate of 18.1% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 7.68%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Interactive Brokers Gr's ROE stands out, surpassing industry averages. With an impressive ROE of 4.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Interactive Brokers Gr's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.13%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Interactive Brokers Gr's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IBKR

Analyst Expectations For Interactive Brokers Gr's Future

11 analysts have shared their evaluations of Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $106.36, along with a high estimate of $117.00 and a low estimate of $96.00. Experiencing a 1.43% decline, the current average is now lower than the previous average price target of $107.90. 
<img src="https://www.benzinga.com/files/images/story/2024/1734724838_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Popular is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$104.00</td>
<td>-</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$116.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$98.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Frank Schiraldi</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$104.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Popular. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Popular compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Popular's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Popular's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BPOP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Popular analyst ratings.</a>
<h2>Discovering Popular: A Closer Look</h2>
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
<h3>Unraveling the Financial Story of Popular</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Popular's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 7.1%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Popular's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 22.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Popular's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.79% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Popular's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.21%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Popular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.18.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPOP

Deep Dive Into Popular Stock: Analyst Perspectives (11 Ratings)

Ratings for Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $112.75, a high estimate of $130.00, and a low estimate of $78.00. A decline of 7.96% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1734724828_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Innovative Ind Props. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Aaron Grey</td>
<td>Alliance Global Partners</td>
<td>Announces</td>
<td>Buy</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$118.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$125.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Innovative Ind Props. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Innovative Ind Props compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Innovative Ind Props's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Innovative Ind Props's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IIPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Innovative Ind Props analyst ratings.</a>
<h2>About Innovative Ind Props</h2>
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
<h3>Financial Milestones: Innovative Ind Props's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Innovative Ind Props faced challenges, resulting in a decline of approximately -1.67% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 51.07%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Innovative Ind Props's ROE stands out, surpassing industry averages. With an impressive ROE of 2.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Innovative Ind Props's ROA stands out, surpassing industry averages. With an impressive ROA of 1.64%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.15.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IIPR

Assessing Innovative Ind Props: Insights From 4 Financial Analysts

In the preceding three months, 6 analysts have released ratings for Pagaya Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Pagaya Techs, presenting an average target of $22.83, a high estimate of $36.00, and a low estimate of $11.00. This current average has decreased by 35.14% from the previous average price target of $35.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1734724820_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Pagaya Techs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rayna Kumar</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Legg</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pagaya Techs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Pagaya Techs compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pagaya Techs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pagaya Techs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PGY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pagaya Techs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Pagaya Techs's Background</h2>
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, big data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
<h3>Pagaya Techs's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Pagaya Techs showcased positive performance, achieving a revenue growth rate of 23.75% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Pagaya Techs's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -27.07%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Pagaya Techs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -13.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Pagaya Techs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.78%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.49, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Pagaya Techs's Future

Did a series of unfortunate events cause funnyman Jim Carrey to finally sell his LA home of 30 years by taking a drop of $10 million from his original asking price? The 10,954-square-foot house in Brentwood went into contract with an asking price of $19.75 million, down from $28.9 million a year ago.&nbsp;
<h2 class="wp-block-heading">Claims To Need Cash</h2>
Carrey had stated in 2022 that he was quitting acting after starring in the <a href="https://www.benzinga.com/general/entertainment/24/04/38174401/paramount-aims-for-sonic-movies-to-reach-avengers-level-status-says-producer">wildly successful</a> &#8220;Sonic the Hedgehog 2,&#8221; but his time off was short-lived. The actor stars in the third installment, which will be released on December 20th. When questioned about the retirement U-turn during the film&#8217;s promotion, Carrey hinted at a cash crunch:
Don't Miss:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=unlockboost-yahoo"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>
&#8220;I came back to this universe because I get to play a genius, which is a bit of a stretch,&#8221;<a href="https://x.com/APEntertainment/status/1866579281045811233?mod=article_inline"> Carrey quipped</a>. &#8220;And you know, <a href="https://www.benzinga.com/news/24/12/42512179/i-bought-a-lot-of-stuff-jim-carrey-admits-joining-other-stars-returning-to-acting-due-to-money-woes-after-retirement">I bought a lot of stuff</a> and I need the money, frankly.&#8221;
The actor, 62, is reported to have a net worth of $180 million. He previously sold a Malibu home for $13.95 million in 2013 and also owns a home in Maui, which is believed to have been purchased in 2017. It is his primary residence. According to Celebrity Net Worth, Carrey also owns an apartment in New York.
Carrey previously told the New York Post of his recently sold LA home:
&#8220;For three decades, it&#8217;s been a sanctuary for me, but I don&#8217;t spend a lot of time there now and I want someone else to enjoy it like I have.&#8221; Carrey still stands to make a fortune by most people&#8217;s standards from selling his LA home, having purchased it way back in 1994 for $3.8 million.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Nineties Heyday</h2>
Carrey&#8217;s career heyday was during the nineties and early oughts when he was the first actor to earn $20 million for a movie and earned at least $300 million from film salaries and bonuses. Box office hits from that era include The Mask, Dumb and Dumber, The Truman Show, Liar Liar and Bruce Almighty. Despite big up front checks, Carrey also made some savvy financial moves. At the height of his fame, he relinquished a big front-end paycheck for the movie &#8220;Yes Man&#8221; in exchange for being a part owner of the movie. It paid off as the film grossed $223 million worldwide, earning Carrey around $30 million.
Carrey&#8217;s recent return to the big screen comes after a significant downturn in his creative output. He has acted in only a handful of films in the last few years, including Sonic the Hedgehog 3, his only film of 2024. According to the Daily Mail, Carrey&#8217;s luxury car collection and global travel have helped him take a bite out of his fortune, which, coupled with his sporadic film work, has caused his net worth to drop. He wouldn't be the first Hollywood star to fall victim to <a href="https://www.benzinga.com/personal-finance/24/10/41418807/al-pacino-went-broke-after-blowing-50-million-on-16-cars-23-cellphones-and-400k-for-landscaping-">profligate luxury car spending</a>.
Trending: <a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf">&nbsp;</a>
<h2 class="wp-block-heading">A More Meaningful Life</h2>
Carrey&#8217;s decision to step away from Hollywood at 62 may have been motivated by a natural desire to lead a more meaningful life away from the entertainment business.
&#8220;I really like my quiet life and I really like putting paint on canvas and I really love my spiritual life and I feel like – and this is something you might never hear another celebrity say as long as time exists – I have enough. I&#8217;ve done enough. I am enough.&#8221;
Clearly, something changed.
Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today.<a href="https://smartasset.com/retirement/find-a-financial-planner?utm_source=benzinga&amp;utm_campaign=ben&amp;utm_content=y2_5MilNestEgg"> SmartAsset&#8217;s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost</a> to decide which one is right for you.
<h2 class="wp-block-heading">Interest Rates Are Falling, But These Yields Aren't Going Anywhere</h2>
Lower interest rates mean some investments won't yield what they did in months past, but you don't have to lose those gains. Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities.
<a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate. The best part? Unlike other private credit funds, <a href="https://www.benzinga.com/go/arrived-private-credit-yf">this one has a minimum investment of only $100.&nbsp;</a>
Looking for fractional real estate investment opportunities? The <a href="https://www.benzinga.com/alternative-investments/real-estate">Benzinga Real Estate Screener</a> features the latest offerings.

Real Estate

No Laughing Matter: Jim Carrey Sells LA Home of 30 Years After $10M Price Drop Amid Claims He Needs The Money

Across the recent three months, 4 analysts have shared their insights on Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $45.0, a high estimate of $50.00, and a low estimate of $41.00. No alteration is observed as the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1734724811_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Vital Farms. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Des Lauiers</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Rob Dickerson</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Brian Holland</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Vital Farms. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Vital Farms compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Vital Farms's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Vital Farms's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VITL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vital Farms analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Vital Farms</h2>
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter &amp; Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
<h3>Vital Farms's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Vital Farms's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 31.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Vital Farms's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.14%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Vital Farms's ROE excels beyond industry benchmarks, reaching 3.03%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Vital Farms's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.24%, the company showcases efficient use of assets and strong financial health.
Debt Management: Vital Farms's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VITL

What 4 Analyst Ratings Have To Say About Vital Farms

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 600 points on Friday.
The Dow traded up 1.55% to 43,000.53 while the NASDAQ rose 1.65% to 19,693.06. The S&amp;P 500 also rose, gaining, 1.53% to 5,956.61.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Real estate shares jumped by 2.4% on Friday.
In trading on Friday, consumer staples shares rose by just 0.4%.
Top Headline
The total number of active U.S. oil rigs climbed by 1 to 483 rigs this week, Baker Hughes Inc reported.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares shot up 40% to $4.8500 after the company announced FDA approval for SYMVESS for treating extremity vascular injuries. HC Wainwright &amp; Co. raised its price target on the stock from $12 to $15.</li>
<li>Shares of Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)got a boost, surging 25% to $6.55 after the company and Moderna recently announced a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157. The company also announced an investment from Merck.</li>
<li>Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares were also up, gaining 37% to $0.4349 after the company announced it received an additional 180 calendar days for compliance with the Nasdaq minimum bid price requirement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 74% to $0.4276 as the company reported the pricing of $20.0 million follow on offering.</li>
<li>Shares of Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) were down 54% to $0.9297 after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was down, falling 17% to $85.72. The company announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE program.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $69.43 while gold traded up 1.5% at $2,648.30.
Silver traded up 2.7% to $30.210 on Friday, while copper rose 0.8% to $4.1075.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 0.88%, Germany's DAX fell 0.43% and France's CAC 40 declined 0.27%. Spain's IBEX 35 Index rose 0.24%, while London's FTSE 100 fell 0.26%.
Consumer confidence in the Eurozone declined by 0.8 points to a reading of -14.5 in December.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 0.29%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index declining 0.06% and India's BSE Sensex falling 1.49%.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, and versus a reading of 71.8 in November.</li>
<li>U.S. personal income increased by 0.3% month-over-month in November compared to a revised 0.7% gain in October.</li>
<li>Personal spending increased by 0.4% to an annualized rate of $20.2 trillion in November.</li>
<li>The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.</li>
<li>The total number of active U.S. oil rigs climbed by 1 to 483 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

GALT

HUMA

PSNL

TAOP

Dow Surges Over 600 Points, Gold Jumps 1.5%

Jabil shares are trading higher after Barclays maintained an Overweight rating on the stock and raised its price target from $157 to $179.

Anshul Dhankher, an analyst from LifeSci Capital, maintained the Buy rating on Perspective Therapeutics (CATX – Research Report). The associated pr...

Promising Potential in Perspective Therapeutics' VMT-alpha-NET Program Amid Market Hesitations

In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report), with a pri...

Cautious Optimism: Justin Walsh's Buy Rating on Perspective Therapeutics Amidst Mixed Trial Results

JonesResearch analyst Justin Walsh views the selloff in shares Perspective Therapeutics (CATX) yesterday after the company reported initial results...

Perspective Therapeutics selloff a buying opportunity, says JonesResearch

Truist Financial analyst Nicole Germino assigned a Buy rating to Perspective Therapeutics (CATX – Research Report) today and set a price target of ...

Truist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)

Oppenheimer lowered the firm's price target on Perspective Therapeutics (CATX) to $16 from $22 and keeps an Outperform rating on the shares. The fi...

Perspective Therapeutics price target lowered to $16 from $22 at Oppenheimer

In a report released on November 22, Alec Stranahan from Bank of America Securities downgraded Perspective Therapeutics (CATX – Research Report) to...

Cautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety Concerns

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Perspective Therapeutics (CATX – Research Report). The compan...

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

BofA analyst Alec Stranahan downgraded Perspective Therapeutics (CATX) to Neutral from Buy with a price target of $6, down from $24, after the comp...

Perspective Therapeutics downgraded to Neutral from Buy at BofA

B. Riley lowered the firm's price target on Perspective Therapeutics (CATX) to $9 from $17 and keeps a Buy rating on the shares. After taking anoth...

Perspective Therapeutics price target lowered to $9 from $17 at B. Riley

Meetings to be held in Denver on December 10 and in Chicago on December 11 hosted by Truist. Published first on TheFly – the ultimate source for re...

Perspective Therapeutics management to meet with Truist

CATX

Press Releases

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Alector

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Perspective Therapeutics

Interés en corto

Perspective Therapeutics (AMEX:CATX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL